The Conversation (0)
Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL
Mar. 22, 2018 08:32AM PST
Biotech InvestingTonix Pharmaceuticals (Nasdaq:TNXP) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today that U.S. Patent No. 9,918,948 was issued on March 20, 2018 by the U.S. Patent and Trademark Office. As quoted in the press release: “This U.S. method of use patent …
Tonix Pharmaceuticals (Nasdaq:TNXP) a clinical-stage biopharmaceutical company focused on developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense, announced today that U.S. Patent No. 9,918,948 was issued on March 20, 2018 by the U.S. Patent and Trademark Office.
As quoted in the press release:
“This U.S. method of use patent for TNX-102 SL strengthens and expands our intellectual property portfolio, which already includes patents protecting novel compositions of TNX-102 SL in the U.S., the novel pharmacokinetic profile of TNX-102 SL in Japan and the use of TNX-102 SL in treating PTSD in Europe” commented Seth Lederman, M.D., President and Chief Executive Officer of Tonix. “Tonix has conducted or sponsored the development of the technology for all of its programs, including the TNX-102 SL program, and therefore does not expect to owe development-based royalties or license fees upon commercialization.”